secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0001213900-24-065292
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL
--------------------------------------------------------------------------------

- First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.
- Target indication: relapsed/refractory B-cell Non-Hodgkin's Lymphomas (R/R B-cell NHL).
- Trial is open-label, dose escalation/expansion to assess safety and determine Recommended Phase II Dose (RP2D).
- Principal Investigator: Naseem Esteghamat, M.D., at UC Davis Comprehensive Cancer Center.
- Clinical trial identifier on ClinicalTrials.gov: NCT06343311.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024065292/0001213900-24-065292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390024065292/ea021066101-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-065292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer